Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Cohance Lifesciences is the renamed entity created by merging Advent International's CDMO platform (built on RA Chem Pharma and ZCL Chemicals) with listed Suven Pharmaceuticals. It is a contract development and manufacturing organisation supplying pharma intermediates, APIs and specialty chemical actives to global innovator pharma and agrochemical companies, with capabilities in areas such as antibody-drug-conjugate payloads and linkers. Revenue is driven by long-cycle CDMO contracts tied to innovator molecule volumes.
Cohance Lifesciences Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Cohance Lifesciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 25.46 crore to 38.26 crore in FY26, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY26 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 4.69 | 10.52 | 11.80 |
| Book value / share (₹) | 105.43 | 72.30 | 80.56 |
| Return on equity | 4.4% | 14.6% | 14.6% |
| Return on capital employed | 4.7% | 11.2% | 16.4% |
| Operating margin | 10.6% | 24.9% | 33.4% |
| Net margin | 6.6% | 22.1% | 28.6% |
| EBITDA | ₹427 Cr | ₹375 Cr | ₹406 Cr |
| Free cash flow | ₹148 Cr | ₹132 Cr | ₹307 Cr |
| Total debt | ₹170 Cr | ₹78 Cr | ₹39 Cr |
| Debt to equity | 0.04 | 0.04 | 0.02 |
| Interest coverage | 6.4 | 24.1 | 47.1 |
| Current ratio | 2.78 | 2.34 | 11.82 |
| Shares outstanding | 38,26,00,000 | 25,46,00,000 | 25,45,65,000 |
Open the full income statement, balance sheet and cash flow for COHANCE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.